Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Heart & blood · 2025

Cardamyst (etripamil)

The FDA approved Cardamyst (etripamil) on December 12, 2025 to treat episodes of paroxysmal supraventricular tachycardia.
Brand name
Cardamyst
Generic name
etripamil
FDA approval date
December 12, 2025
Approved use (FDA wording)
To treat episodes of paroxysmal supraventricular tachycardia
Company
Milestone Pharms Usa
Application
NDA218571
Dosage form / route
SPRAY · NASAL
Boxed warning on label
Not listed
Category on this site
Heart & blood

Indications and usage, from the FDA label

CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults ( 1 ).

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.